Mereo BioPharma Group (MREO) News Today $2.18 -0.06 (-2.68%) Closing price 04:00 PM EasternExtended Trading$2.24 +0.06 (+2.94%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MREO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Buys Shares of 618,784 Mereo BioPharma Group plc (NASDAQ:MREO)Woodline Partners LP bought a new stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 618,784 shares of the company's stock, valued at approximately $2,166,000. WMay 27 at 4:31 AM | marketbeat.comTema Etfs LLC Invests $3.12 Million in Mereo BioPharma Group plc (NASDAQ:MREO)Tema Etfs LLC acquired a new position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 890,548 shares of the company's stock, valued at approximately $3,117,000. Mereo BioPharma Group comprMay 20, 2025 | marketbeat.comMereo BioPharma Group (MREO) to Release Earnings on WednesdayMay 19, 2025 | americanbankingnews.comMREO FY2025 EPS Estimate Increased by Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Outlook for MREO EarningsMay 17, 2025 | americanbankingnews.comJanus Henderson Group PLC Boosts Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)Janus Henderson Group PLC boosted its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 38.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,122,563 shares of tMay 16, 2025 | marketbeat.comMereo BioPharma Group (MREO) to Release Quarterly Earnings on WednesdayMereo BioPharma Group (NASDAQ:MREO) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-mereo-biopharma-group-plc-stock/)May 16, 2025 | marketbeat.comWe're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn RateMay 15, 2025 | finance.yahoo.comMereo BioPharma Group (NASDAQ:MREO) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday.May 15, 2025 | marketbeat.comMereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | finanznachrichten.deMereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Purchases Shares of 493,900 Mereo BioPharma Group plc (NASDAQ:MREO)Schonfeld Strategic Advisors LLC acquired a new position in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 493,900 shares of the company's stocMay 8, 2025 | marketbeat.com225,000 Shares in Mereo BioPharma Group plc (NASDAQ:MREO) Purchased by Cantor Fitzgerald L. P.Cantor Fitzgerald L. P. acquired a new stake in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 225,000 shares of the company's stock, valued at approximately $788,000. Cantor FitzgeraldMay 7, 2025 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Given Average Rating of "Buy" by BrokeragesMereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recoMay 6, 2025 | marketbeat.comAcuta Capital Partners LLC Sells 481,392 Shares of Mereo BioPharma Group plc (NASDAQ:MREO)Acuta Capital Partners LLC reduced its holdings in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 38.2% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 779,308 shares of the company's stock after selling 481,May 4, 2025 | marketbeat.com683 Capital Management LLC Trims Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)683 Capital Management LLC cut its holdings in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,550,000 shares of the company'sMay 4, 2025 | marketbeat.comMarshall Wace LLP Lowers Stake in Mereo BioPharma Group plc (NASDAQ:MREO)Marshall Wace LLP cut its stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 15.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 866,317 shares of the company's stock after selling 162,195 shares duringApril 29, 2025 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Stock Position Lowered by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. lowered its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 10.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,715,013 shares of the compApril 28, 2025 | marketbeat.comBlue Owl Capital Holdings LP Trims Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)Blue Owl Capital Holdings LP lessened its stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 20.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 672,809 shares of the company's stock after selling 175,000April 26, 2025 | marketbeat.comWalleye Capital LLC Makes New Investment in Mereo BioPharma Group plc (NASDAQ:MREO)Walleye Capital LLC bought a new stake in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 129,629 shares of the company's stock, valued at approximately $454,000. WallApril 26, 2025 | marketbeat.comRenaissance Technologies LLC Sells 115,900 Shares of Mereo BioPharma Group plc (NASDAQ:MREO)Renaissance Technologies LLC lowered its stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 8.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,189,471 shares of the company's stock after selling 115,900 shares during the quarter. RenaissanApril 23, 2025 | marketbeat.comMereo BioPharma Group plc (MREO): A Bull Case TheoryApril 18, 2025 | finance.yahoo.comIs Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comMereo BioPharma Group plc (NASDAQ:MREO) Given Average Recommendation of "Buy" by BrokeragesMereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has received an average rating of "Buy" from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy ratingApril 12, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research note on Wednesday.April 11, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Mereo Biopharma Group Plc (MREO) and Doximity (DOCS)April 9, 2025 | markets.businessinsider.comMereo BioPharma’s SWOT analysis: rare disease stock poised for breakthroughApril 2, 2025 | uk.investing.comCantor Fitzgerald Forecasts MREO FY2025 EarningsMereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mereo BioPharma Group in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($0.08)March 31, 2025 | marketbeat.comResearch Analysts Offer Predictions for MREO Q1 EarningsMereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Mereo BioPharma Group in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will earn $0.07 per share for the quarterMarch 31, 2025 | marketbeat.comJPMorgan Chase & Co. Begins Coverage on Mereo BioPharma Group (NASDAQ:MREO)JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a report on Thursday. They set an "overweight" rating and a $7.00 price target on the stock.March 28, 2025 | marketbeat.comMereo BioPharma initiated with an Overweight at JPMorganMarch 27, 2025 | markets.businessinsider.comCantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)March 27, 2025 | markets.businessinsider.comJP Morgan Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Overweight RecommendationMarch 27, 2025 | msn.comMereo BioPharma Group's (MREO) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Wednesday.March 27, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Releases Earnings Results, Misses Estimates By $0.03 EPSMereo BioPharma Group (NASDAQ:MREO - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03).March 27, 2025 | marketbeat.comMereo BioPharma sees cash runway into 2027March 27, 2025 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Allurion Technologies (ALUR), Savara (SVRA)March 27, 2025 | markets.businessinsider.comMereo BioPharma Group plc: Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate HighlightsMarch 26, 2025 | finanznachrichten.deMereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate HighlightsMarch 26, 2025 | globenewswire.comMereo BioPharma’s SWOT analysis: setrusumab, alvelestat drive rare disease stock potentialMarch 21, 2025 | uk.investing.comMereo BioPharma Group (NASDAQ:MREO) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Mereo BioPharma Group in a report on Tuesday.March 19, 2025 | marketbeat.comTejara Capital Ltd Reduces Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)Tejara Capital Ltd decreased its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 18.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,317,085 shares of the company's stock after selling 5March 19, 2025 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Rating of "Buy" from BrokeragesMereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and three have given a strong buy recommendMarch 16, 2025 | marketbeat.comMereo BioPharma management to meet with Cantor FitzgeraldMarch 11, 2025 | markets.businessinsider.comHidden Gems: 5 Stocks Under $10 With Massive Growth Potential (MREO)Uncover five promising stocks under $10, each poised for gains across diverse sectors for the second quarter of 2025.March 11, 2025 | marketbeat.comMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comHealthInvest Partners AB Has $1.37 Million Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)HealthInvest Partners AB lifted its position in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 95.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,000 shares of the coFebruary 24, 2025 | marketbeat.comAptos Price Forecast: APT and Mereo partnership fuels investors’ optimism as K-Pop fan engagement evolvesFebruary 20, 2025 | fxstreet.comMereo BioPharma: Good Science, Fairly ValuedFebruary 11, 2025 | seekingalpha.comMereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Recommendation of "Buy" from AnalystsShares of Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) have been given an average rating of "Buy" by the seven analysts that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating and three have given a strong buy rating toJanuary 25, 2025 | marketbeat.com Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address MREO Media Mentions By Week MREO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MREO News Sentiment▼1.801.03▲Average Medical News Sentiment MREO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MREO Articles This Week▼22▲MREO Articles Average Week Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GPCR News Today TVTX News Today MESO News Today ETNB News Today ADPT News Today DYN News Today VERA News Today ANIP News Today CALT News Today OCUL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MREO) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
